Studies in immune-deficient mice engrafted with human CRC cells showed that locally administered mesalazine (50 mM) significantly reduced the growth of xenografts, and this effect was blocked by a selective PPAR-γ antagonist [69]. The gene discussed is PPARG; the disease is colorectal carcinoma.